Abstract
Although the precise etiology of inflammatory bowel diseases (IBD) still remains unclear, considerable progress has been made in the identification of novel signal transduction pathways that elucidate the immunopathogenesis involved in the perpetuation of the inflammatory process. As both ulcerative colitis and Crohns disease are associated with an increased risk for developing colorectal cancer (CRC) and precancerous dysplastic epithelial changes, further studies have concentrated on finding a common signaling pathway that could serve as a mechanistic link between inflammation and associated colonic cancer in IBD. This review presents the current data concerning the pathogenic role of the IL-6/STAT-3 trans signaling pathway in IBD and colorectal cancer. Furthermore it evaluates the possible therapeutic potential of targeting this pathway for the therapy of IBD and CRC.
Keywords: IBD, colon cancer, IL-6, trans signaling, STAT-3, Bcl-xl
Current Drug Targets
Title: Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer
Volume: 9 Issue: 5
Author(s): R. Atreya and M. F. Neurath
Affiliation:
Keywords: IBD, colon cancer, IL-6, trans signaling, STAT-3, Bcl-xl
Abstract: Although the precise etiology of inflammatory bowel diseases (IBD) still remains unclear, considerable progress has been made in the identification of novel signal transduction pathways that elucidate the immunopathogenesis involved in the perpetuation of the inflammatory process. As both ulcerative colitis and Crohns disease are associated with an increased risk for developing colorectal cancer (CRC) and precancerous dysplastic epithelial changes, further studies have concentrated on finding a common signaling pathway that could serve as a mechanistic link between inflammation and associated colonic cancer in IBD. This review presents the current data concerning the pathogenic role of the IL-6/STAT-3 trans signaling pathway in IBD and colorectal cancer. Furthermore it evaluates the possible therapeutic potential of targeting this pathway for the therapy of IBD and CRC.
Export Options
About this article
Cite this article as:
Atreya R. and Neurath F. M., Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer, Current Drug Targets 2008; 9 (5) . https://dx.doi.org/10.2174/138945008784221116
DOI https://dx.doi.org/10.2174/138945008784221116 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry Comparison of the Effects of Diltiazem Gel with Lidocaine Gel on Reducing Pain and Discomfort in Patients Undergoing Rectosigmoidoscopy: A Randomized Double-blinded Clinical Trial
Current Drug Therapy Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
Current Drug Targets Painting the Target Around the Arrow: Two-Step Prodrug Therapies from a Carbohydrate Chemists Perspective
Current Drug Delivery Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World
Clinical Cancer Drugs Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets Proline Oxidase (POX) as A Target for Cancer Therapy
Current Drug Targets (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Age- Related Macular Degeneration
Current Drug Therapy Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy Pharmacokinetics and In Vivo Fate of Drug Loaded Chitosan Nanoparticles<sup>++</sup>
Current Drug Metabolism Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry